Enzymatica’s Board of Directors decides on a new rights issue of SEK 59.1 million
The Board of Directors of Enzymatica AB (publ) (“Enzymatica” or the “Company”) has decided to carry out a rights issue amounting to SEK 59.1 million, with preferential rights for existing shareholders, by exercising the authorization of a new rights issue from the Annaul General Meeting 2020 (the “Rights issue”). The purpose of the Rights issue is above all to enable the Company’s offensive geographical expansion and clinical studies, and in addition, meet the need of working capital for 2021. Under the terms of the Rights issue, one (1) existing share in Enzymatica carries one (1)